The design and synthesis of thrombin inhibitors: Analogues of MD805 containing non-polar surrogates for arginine at the P1 position

Bioorganic and Medicinal Chemistry Letters

Volumn 10, Issue 14, 2000, Pages 1563-1566

  Baettig, Urs ^a   Brown, Lyndon ^a   Brundish, Derek ^a   Dell, Colin ^a   Furzer, Alex ^a   Garman, Sheila ^a   Janus, Diana ^a   Kane, Peter D ^a   Smith, Garrick ^a   Walker, Clive V ^a   Cockcroft, Xiaoling ^a   Ambler, John ^a   Mitchelson, Andrew ^a   Talbot, Mark D ^a   Tweed, Morris ^a   Wills, Nicholas ^a  

^a NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE DERIVATIVE; AMINO ACID DERIVATIVE; ARGATROBAN; ARGININE; THROMBIN; THROMBIN INHIBITOR;

ARTICLE; CHEMICAL MODIFICATION; DRUG DESIGN; DRUG SELECTIVITY; DRUG SYNTHESIS;

ALANINE; ANTITHROMBINS; ARGININE; CHYMOTRYPSIN; DRUG DESIGN; FACTOR XA; KALLIKREINS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PIPECOLIC ACIDS; PLASMIN; SERINE PROTEINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; THROMBIN; TRYPSIN;

EID: 0034679850     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(00)00282-1     Document Type: Article

References (18)

1. Fenton, J. W. Semin. Thromb. Haemost. 1988, 14, 234.
2. (b) Vu, T. K. H.; Hung, D. T.; Wheaton, V. I.; Coughlin, S. R. Cell. 1991, 64, 1057.
3. (a) Callas, D.; Fareed, J. Thromb. Haemost. 1995, 74, 473.
4. (b) Weitz, J. Int. J. Clin. Pract. 1997, Issue Suppl. 90, 25.
5. (c) Verstraete, M. Thromb. Haemost. 1997, 78, 357.
6. (a) Brundish, D. E. Current Opinion in Therapeutic Patents, Current Drugs Ltd, 1992, pp 1457-1466.
7. (b) Ripka, W. C. Curr. Opin. Chem. Biol. 1997, 1, 242.
8. (c) Wiley, M. R.; Fisher, M. J. Expert Opin. Ther. Pat. 1997, 7, 1265.
9. (d) Hauptmann, J; Sturzebecher, J. Thromb. Res. 1999, 93, 203.
10. Okamoto S., Hijikata A. J. Med. Chem. 23:1980;1293.
11. Misra R.N., Kelly Y.F., Brown R.B., Roberts D.G.M., Chong S., Seiler S.M. Bioorg. Med. Chem. Lett. 4:1994;2165.
12. Nestor J.J. Jr., Horner B.L., Ho T.L., Jones G.H., McRae G.I., Vickery B.H. J. Med. Chem. 27:1984;320.
13. Cava P., Levinson M.I. Tetrahedron. 41:1985;5061.
14. Brundish D., Bull A., Donovan D., Fullerton J.D., Garman S., Hayler J., Janus D., Kane P.D., McDonnell M., Smith G.P., Wakeford R., Walker C.V., Howarth G., Hoyle W., Allen M.C., Ambler J., Butler K., Talbot M.D. J. Med. Chem. 42:1999;4584.
15. 10 and the piperidine moiety occupying S2. For convenience we term MTHQS and DMTHQS P3 and the piperidide moiety P2.
16. Banner, D.; Ackermann, J.; Gast, A.; Gubernator, K.; Hadvary, P.; Hilpert, K.; Labler, L.; Mueller, K.; Schmid, G. Serine Proteases: 3-D Structures, Mechanisms of Action and Inhibitors. In Perspectives in Medicinal Chemistry; Testa, B., Ed.; Verlag Helvetica Chim. Acta: Basel, Switzerland, 1993, 27.
17. Allen M.C., Cockcroft X.L., Gruetter M.G., Priestle J.P. J. Comp.-Aided Mol. Des. 13:1999;579.
18. Details concerning acyclic P1 inhibitors of this type will be published elsewhere.